February 15, 2019
An Akorn Inc. investor told an Illinois federal court the pharmaceutical company's executives should not be able to dodge a suit alleging they lied in public statements for their own benefit, concealed regulatory problems and sunk a major merger deal with their inept behavior.
January 15, 2019
Akorn Inc. told an Illinois federal judge on Monday that a shareholder's consolidated derivative suit claiming the pharmaceutical company's falsified regulatory submissions sunk a multibillion-dollar merger and tanked Akorn's share price doesn't offer allegations to support a securities claim and must be tossed.
November 07, 2018
An Akorn Inc. shareholder sued the pharmaceutical company's executives and board members on Tuesday in Illinois federal court over falsified submissions to the U.S. Food and Drug Administration, a "debacle" that sunk a multibillion-dollar merger and plunged Akorn's share price by nearly 50 percent.